BIRC5 and nonpapillary renal cell carcinoma: Accumulating evidence shows that BIRC5 (also known as survivin) is closely related to tumor progression, tumor progression, tumor recurrence, chemotherapy resistance and poor prognosis (Liu et al., 2015; Zhang et al., 2019c), and high expression levels of BIRC5 predicted a poor outcome for ccRCC patients (Parker et al., 2006).